

科別	適應症	試驗計畫名稱	期別	JIRB編號	計畫主持人	聯絡人
Department	Indication	Protocol name	Phase	JIRB No.	Investigator name	Contact
	Extension Study 延伸性試驗	An Extension Study to Provide Oraxol to Patients who Completed KX-ORAX-007 一項延伸性試驗提供Oraxol給完成KX-ORAX-007試驗的受試者	I	N201708038	Shiah Her-Shyong 杜世興	藍偉玲
	Clinical Study 臨床試驗	A Clinical Study to Determine the Pharmacokinetics of Oraxol in Breast Cancer Patients 一項確認Oraxol於乳癌患者藥物動力學之臨床試驗	I/PK	N201609012	Shiah Her-Shyong 杜世興	藍偉玲
	Non-Small Cell Lung Cancer 非小細胞肺癌	A randomized, double-blind, multicenter, placebo-controlled, parallel, pilot study to evaluate the quality of life improvement of oral Oligo Fucoidan as an adjuvant in subjects receiving platinum-based chemotherapy with Non-Small Cell Lung Cancer (NSCLC) 一項隨機、雙盲、多中心、安慰劑對照、平行、前導性臨床試驗，評估以口服小分子褐藻醣膠(Oligo Fucoidan)做為非小細胞肺癌(NSCLC)受試者鉑類化療之輔劑對生活品質的改善	NA	N201610001	Her-Shyong Shiah 夏和雄	藍偉玲
	乳癌	一項隨機、多中心、雙盲、安慰劑對照、第三期試驗，在早期或局部晚期Her2陽性乳癌患者中，評估以Pertuzumab併用Docetaxel和Trastuzumab的術前輔助治療，以及手術和化療後以Pertuzumab併用Trastuzumab的輔助治療	III	201411040	Shiah Her-Shyong 杜世興	藍偉玲
	Bone Tumors 骨髓瘤	Safety and Effectiveness Comparison of ExAblate MR guided Focused Ultrasound Bone System and External Beam Radiation for Treatment of Metastatic Bone Tumors and Multiple Myeloma 磁共振導引聚焦超音波骨系統和體外射束放射用於轉移性骨腫瘤和多發性骨髓瘤治療的安全性和有效性比較	IV	N201602052	Jeng-Fong Chiou 邱仲峰	NA
	Non-Small Cell Lung Cancer 非小細胞肺癌	Randomized, Open-Label Phase 3 Trial of Nivolumab and Ipilimumab versus Platinum-Doublet Chemotherapy in Early Stage NSCLC 一項開放性、隨機分配、第三期試驗，以Nivolumab併用Ipilimumab相較於鉑類複合化療，用於早期非小細胞肺癌(NSCLC)的病患	III	N201707010	Her-Shyong Shiah 夏和雄	徐珮娟 0970-405-546

血液 腫瘤	Non-Small Cell Lung Cancer 非小細胞肺癌	Open-Label, Randomized Trial of Nivolumab (BMS-936558) plus Pemetrexed/Platinum or Nivolumab plus Ipilimumab (BMS-734016) vs Pemetrexed plus Platinum in Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) Subjects with Epidermal Growth Factor Receptor (EGFR) Mutation, T790M Negative Who Failed 1L EGFR Tyrosine Kinase Inhibitor Therapy 針對上皮細胞生長因子受體 (EGFR) 突變、T790M 陰性且第一線(1L) EGFR 酪胺酸激酶抑制劑治療失敗的第四期或復發性非小細胞肺癌 (NSCLC) 受試者，給予Nivolumab (BMS-936558) 加 Pemetrexed/鉑 (platinum) 或Nivolumab 加 Ipilimumab (BMS-734016) · 相較於Pemetrexed 加鉑之開放性、隨機分配試驗	III	N201705038	Her-Shyong Shiah 夏和雄	陳怡安 0970-405073
	Chronic Lymphocytic Leukemia 慢性淋巴性白血病	Molecular Features Underlying Racial Differences in Survival of Taiwanese Chronic Lymphocytic Leukemia Patients 台灣慢性淋巴性白血病族群存活差異背後之分子特徵	Others	N201512039	Her-Shyong Shiah 夏和雄	陳怡安 0970-405073
	鼻咽癌	鼻咽癌患者治療緩解後 E B 病毒再活化與膳食補充品兒茶素對病毒再活化之影響隨機分組試驗	II	201309003	劉滄梧/彭汪嘉康	武曉薇 0970-405-535
	頭頸癌	第三或第四期頭頸部鱗狀細胞癌胞手術後輔助性同步放射與化學治療時，有或沒有加入 Nimotuzumab 的隨機、雙盲、安慰劑控制操作之第三期臨床試驗	III	CRC-02-10-03	丁禮莉	武曉薇 0970-405-535
	局部晚期胰臟癌	在局部侵犯之胰臟癌病患，給予引導式化學治療與同步放射治療併化學治療的隨機分配第二相臨床試驗	II	201309005	Her-Shyong Shiah 夏和雄	武曉薇 0970-405-535

結腸炎	<p>A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients with Moderately to Severely Active Ulcerative Colitis LUCENT 1</p> <p>一項第 3 期、多中心、隨機分配、雙盲、平行分組、在常規治療失敗及生物製劑治療失敗的中度至重度活動性潰瘍性結腸炎病患使用Mirikizumab的安慰劑對照誘導試驗</p>	III	N201808008	魏柏立	湯惠珍
結腸直腸癌	<p>阿斯匹林對Dukes C期和伴有高危險因素 Dukes B 期結腸直腸癌的作用, 一項國際性, 多中心, 雙盲, 隨機安慰劑對照III期試驗</p>	III	201108007	魏柏立	湯惠珍
晚期肝細胞癌	<p>An Open-label Phase 2 Trial of Dual TORC1/TORC2 Inhibitor ATG-008 in HBV+ Advanced Hepatocellular Carcinoma (HCC) Subjects Who Have Received at Least One Prior Line of Systemic Therapy (TORCH)</p> <p>一項評估TORC1/TORC2雙重抑制劑ATG-008用於接受過至少一線全身性治療的B型肝炎病毒陽性晚期肝細胞癌受試者之開放性第二期試驗(TORCH)</p>	II	N201803003	Wei-Yu Kao 高偉育	陳怡安
Colon cancer 大腸癌	<p>A randomized Phase III trial of maintenance tegafur-uracil versus observation following adjuvant oxaliplatin-based regimen in patients with stage III colon cancer after radical resection.</p> <p>比較給予tegafur-uracil 與觀察組用於根除性切除第三期大腸癌病患在使用過 oxaliplatin-based 輔助性治療後維持性療法之前瞻性隨機臨床試驗。</p>	III	N201512027	Po-Li Wei 魏柏立	湯惠珍
Psoriatic Arthritis 乾癬性關節炎	<p>Cross-sectional Observational study evaluating clinical specialty setting as determinant of management of Patients with Psoriatic Arthritis</p> <p>評估臨床專業作為乾癬性關節炎(PsA)病患處置之決定因子的橫斷研究法觀察性試驗</p>	NA	N201703074	Chi-Ching Chang 張棋楨	N

風濕 免疫	類風濕性關節炎	A 12 week randomized, Double-blind, Double Dummy, Parallel Group, Active And Placebo-Controlled, Multicenter Study To Assess The Efficacy And Safety Profile Of Pf-06650833 In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To Methotrexate 一項為期 12 週、隨機分配、雙盲、雙模擬、平行分組、活性對照與安慰劑對照、多中心試驗、針對Methotrexate反應不佳的活動性類風濕性關節炎受試者、評估PF 06650833 的療效與安全性概況	II	N201703046	Chi-Ching Chang張棋楨	李寧馨
	類風濕性關節炎	A Randomized, Double-blind, Placebo-and Active-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 52 weeks in Combination with Methotrexate to Subjects with Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate 一項隨機分配、雙盲、安慰劑和活性藥物對照、多中心、第三期試驗、在罹患中至重度活動性類風濕性關節炎、且對 Methotrexate 療效反應不足的受試者中、評估 Filgotinib 與 Methotrexate 併用 52 週的療效及安全性	III	N201612017	Chi-Ching Chang張棋楨	李寧馨
	脊椎關節炎	多中心、開放性 (A部分) 後進行隨機分配、雙盲、平行分組、安慰劑對照試驗 (B部分)、針對患有活性軸心型脊椎關節炎 (axSpA) 的受試者、接受Certolizumab pegol 200mg每2週一次 (Q2W) 或200每4週一次 (Q4W)、相較於安慰劑治療、評估維持緩解的效果。	III	N201509019	Chi-Ching Chang張棋楨	全面
	類風濕性關節炎	Phase 2, Randomized, Multi-Center, Double-Blind, Dose-Ranging, Placebo Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety/Pharmacokinetics of BMS-986142 in Subjects with Moderate to Severe Rheumatoid Arthritis with an Inadequate Response to Methotrexate with or without TNF Inhibitors 第2期、隨機分配、多中心、雙盲、劑量範圍、安慰劑對照的調整設計試驗、針對罹患中度至重度類風濕性關節炎且對Methotrexate併用或不併用腫瘤壞死因子 (TNF)抑制劑反應不足的受試者、評估BMS-986142的療效與安全性/藥物動力學	II	N201604029	Chi-Ching Chang張棋楨	全面

	膝關節炎	A Phase IIa, Randomized, Double blinded, Placebo-controlled, Dose-finding Study for Single-dose Administration of TLC599 in Patients with Osteoarthritis (OA) of Knee 以單一劑量 TLC599注射退化性膝關節炎病患之一項第IIa期、隨機分配、雙盲、安慰劑對照、劑量探索臨床試驗	II	N201609008	Chi-Ching Chang 張棋楨	常子芸
腎臟 內科	臨床應用	Investigation of immunoglobulin biomarkers for IgA nephropathy: From mass spectrometry based method development to clinical applications IgA腎炎生物標記開發:免疫球蛋白及其醣化肽質譜分析技術建立與臨床應用		N201704064	Chih-Chin Kao 高治圻	湯惠珍
	End Stage Renal Disease 末期腎病	A Long-Term, Open-Label, Prospective Observational Phase IV Study to Assess the Safety and Efficacy of Nephoxil® in Subjects with End Stage Renal Disease (ESRD) on Dialysis. 一項長期、開放、前瞻性的觀察性第四期試驗，以評估拿百磷®於接受透析之末期腎病(ESRD)病患之安全性與有效性	IV	N201612068	Mai-Szu Wu 吳麥斯	林億萍
	hemodialysis 血液透析	Periodontitis, inflammation and mortality in hemodialysis patients 牙周病治療對血液透析病患預後之影響	IV	N201604007	Mai-Szu Wu 吳麥斯	湯惠珍
	Thrombotic Microangiopathies 血栓性微血管病變	A Phase 2, Uncontrolled, Three-Stage, Dose-Escalation Cohort Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Clinical Activity of OMS721 in Adults with Thrombotic Microangiopathies 評估OMS721使用於血栓性微血管病變成人患者的安全性、藥動學、藥效學、免疫原性與臨床活性的第2期、未對照、三階段、劑量增加組別研究	II	N201510051	Mai-Szu Wu 吳麥斯	徐珮娟
	Asian	A Multicenter, Multiple-dose, Active-controlled, Double-blind, Double dummy Study to Compare the Therapeutic				陳怡安

	<p>Hemodialysis Subjects with Secondary Hyperparathyroidism 患有次發性副甲狀腺機能亢進的亞洲血液透析受試者</p>	<p>Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet Hydrochloride with Intravenous Doses of Etelcalcetide (AMG 416) in Asian Hemodialysis Subjects with Secondary Hyperparathyroidism 一項多中心、多劑量、有效藥物對照、雙盲、雙模擬試驗，比較口服 Cinacalcet Hydrochloride 與靜脈注射Etelcalcetide (AMG 416)，用於患有次發性副甲狀腺機能亢進的亞洲血液透析受試者之療效及安全性</p>	III	N201710010	林彥仲	0970-405073
	糖尿病腎臟疾病	<p>A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone on the reduction of cardiovascular morbidity and mortality in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease in addition to standard of care 一項隨機分配、雙盲、安慰劑對照、平行分組、多中心、以事件為導向的第III期試驗，針對臨床診斷患有糖尿病腎臟疾病的第2型糖尿病受試者，研究使用標準照護加上 finerenone治療在降低心血管發病率以及死亡率上的療效與安全性</p>	III	N201509034	Mai-Szu Wu 吳麥斯	全面
	血管疾病	<p>隨機分配、雙盲、安慰劑對照、平行組別試驗，評估患有第二型糖尿病並確定有血管疾病的受試者，以Ertugliflozin (MK-8835/PF-04971729)治療後的心血管結果</p>	III	201402038	Chen-Ling Huang 黃千玲	藍偉玲
	Diabetes 糖尿病	<p>6-Month, Multicenter, Randomized, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® in Insulin-Naïve Patients with Type 2 Diabetes Mellitus (T2DM) not Adequately Controlled with Non-Insulin Antihyperglycemic Drugs 一項六個月、多中心、隨機分配、平行分組試驗，針對以非胰島素降血糖藥物控制不佳且未曾接受胰島素治療的第二型糖尿病患者，比較Insulin Glargine新劑型與Lantus®(蘭德仕)的療效和安全性</p>	IV	N201703045	Chen-Ling Huang 黃千玲	全面

內分泌與代謝科	Diabetes 糖尿病	A Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro, Both in Combination with Insulin Glargine or Insulin Degludec in Adults with Type 2 Diabetes PRONTO-T2D 針對患有第二型糖尿病的成人·比較LY900014與胰島素Lispro同時併用胰島素Glargine或胰島素Degludec下·一項前瞻性、隨機分配、雙盲試驗 PRONTO-T2D	III	N201705039	Chen-Ling Huang 黃千玲	李寧馨
	Diabetes 糖尿病	6-Month, Multicenter, Randomized, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® in Insulin-Naïve Patients with Type 2 Diabetes Mellitus (T2DM) not Adequately Controlled with Non-Insulin Antihyperglycemic Drugs 一項六個月、多中心、隨機分配、平行分組試驗·針對以非胰島素降血糖藥物控制不佳且未曾接受胰島素治療的第二型糖尿病患·比較Insulin Glargine新劑型與Lantus®(蘭德仕)的療效和安全性	III	N201703045	Chen-Ling Huang 黃千玲	李宛臻
泌尿科	Healthy Adult Volunteers 健康受試者	健康受試者於空腹情況下進行血液採集使用於檢品分析方法之開發、確效及樣品分析 (BM-T042-1601)	其他-血液檢品分析方法之開發、確	N201701024	Ming-Che Liu 劉明哲	丁充達 (U2) 2737-#1980
	Healthy Adult Volunteers 健康受試者	A Phase 2, Double-blind, Randomized Controlled Study to Evaluate Immunogenicity and Safety of Intranasal Trivalent Influenza Virus Vaccine in Healthy Adult Volunteers(AD07030-201)	Phase II	N201706060	Ming-Che Liu 劉明哲	丁充達
	Healthy Adult Volunteers 健康受試者	比較兩種Leuprolide 3.75&11.25mg由健康受試者在進食的情況下口服單劑量、隨機、雙向交叉之生體相等性預試驗	其他-生體相等性試驗 (BE study)	N201711076	Ming-Che Liu 劉明哲	湯惠珍
	Healthy Adult Volunteers 健康受試者	A randomized, single-dose, two-way crossover study to evaluate the bioequivalence of two formulations of clarithromycin tablets (250 mg/tablet) after oral administration in healthy subjects under fasting conditions 一項隨機、單劑量及雙交叉設計用以評估健康受試者在空腹情況下口服投與兩種 clarithromycin 錠劑 (250 mg/錠劑) 藥品之生體相等性試驗 (N201806047)	其他-生體相等性試驗 (BE study)	N201806047	Ming-Che Liu 劉明哲	湯惠珍
		A randomized, single-dose, two-way crossover study to evaluate the				湯惠珍

	Healthy Adult Volunteers 健康受試者	crossover study to evaluate the bioequivalence of two formulations of clarithromycin tablets (250 mg/tablet) after oral administration in healthy subjects under fed conditions. 一項隨機、單劑量及雙交叉設計用以評估健康受試者在進食情況下口服投與兩種 clarithromycin 錠劑 (250 mg/錠劑) 藥品之生體相等性試驗 (N201806048)	其他-生體相等性試驗 (BE study)	N201806048	Ming-Che Liu 劉明哲	0970-405-536
	Healthy Adult Volunteers 健康受試者	Validation test for manufacture of autologous fibroblast cell sheet 自體纖維母細胞製程確效試驗	其他-醫材	N201808026	Ming-Che Liu 劉明哲	曾睦捷 0970-405-559
	Healthy Adult Volunteers 健康受試者	A randomized, single-dose, three-way, partial replicate crossover study to evaluate bioequivalence of two formulations of albendazole (200 mg/tablet) after oral administration in healthy volunteers under fasting conditions 比較兩種albendazole錠劑(200 mg/tablet)由健康受試者在空腹情況下口服單劑量、隨機、三向交叉且部分重複之生體相等性預試驗	其他-生體相等性試驗 (BE study)	N201803068	Ming-Che Liu 劉明哲	李心平
病理科	Retrospective study 驗證計畫	Clinical validation of GB HER2 RealEx PCR – a retrospective, multi-center study in Taiwan 第二型人類表皮生長因子接受體(HER2)即時定量檢驗之臨床性能驗證計畫--國內多中心回溯性驗證	NA	N201602023	Chi-Long Chen 陳志榮	朱郁芬 #1483
胸腔內科	曾參與之前 dupilumab氣喘臨床試驗的患者	Open-label extension study to evaluate the long-term safety and tolerability of dupilumab in patients with asthma who participated in a previous dupilumab asthma clinical study 一項評估 dupilumab長期安全性及耐受性的開放性延伸試驗·對象為曾參與之前dupilumab氣喘臨床試驗的患者	其他- 延伸試驗	N201608009	Chi-Li Chung 鍾啟禮	徐珮娟 0970-405-546
	不吸菸肺癌高危險群	以低劑量電腦斷層掃描篩檢台灣不吸菸肺癌高危險群之研究(第二期)	其他-觀察型研究	N201707035	Chi-Li Chung 鍾啟禮	徐珮娟 0970-405-546
	醫材	Clinical trial of Wrist-Worn Pulse Oximeter 腕戴式血氧儀臨床試驗	新醫療器材	N201807014	Han-Pin Kuo 郭漢彬	曾睦捷

放射腫瘤	Translational Medicine 轉譯醫學	Application of platelet concentrates in translational regenerative medicine and cancer therapy 血小板濃縮液在轉譯再生醫學及癌症治療之應用	其他-人類血液產品研究(不回輸入人體)	N201704002	Yao-Ru Huang/ Ming-Che Liu 黃姚儒/劉明哲	丁充達
心臟內科	冠狀動脈疾病症	MILES - Global: Post Marketing, Multicenter, Single Arm, Observational Clinical Registry to Evaluate Safety and Efficacy of BioMime Sirolimus Eluting Stent System In All Comers Real World Population With Coronary Artery Stenosis MILES全球登錄計畫：針對已上市產品拜歐邁冠狀動脈塗藥支架，在多中心進行單臂臨床觀察研究，針對所有冠狀動脈疾病症患者，經裝置拜歐邁塗藥支架後，評估拜歐邁塗藥支架的安全及有效性。	NA	N201704051	Chun-Yao Huang 黃群耀	章盈萱
	急性靜脈血栓栓塞	全球性抗凝血領域登錄研究，觀察治療經治療後之急性靜脈血栓栓塞病患，其實務上之治療及成果。	IV	201507008	Chun-Yao Huang 黃群耀	武曉薇 0970-405-535
牙科	組織損傷	Autologous mucosal cell products for repairing defects in the esophagus: process validation for use in clinical research 自體口腔細胞層片修復食道組織損傷應用產品之確效試驗	其他-醫材	N201801006	Chia-Yu Wu 吳家佑	曾睦捷
	顳顎障礙症	Hyaluronic acid and platelet-rich plasma on cartilage regeneration in Temporomandibular Joint Osteoarthritis(TMJOA) Therapy 透明質酸(HA)及生長因子複合物(PRP)對改善顳顎障礙症之臨床試驗計畫		N201711041	Bou-Yue Peng 彭伯宇(黃瓊芳)	湯惠珍
	構音障礙病	Speech Recording in Dysarthria Patients 構音障礙病人之聲音樣本收集	Other	N201607030	Chien-Hung Lai 賴建宏	江佳諭 1E+09

復健	神經發展障礙	Prevention of neurodevelopmental disability in high risk infants – Computerized General Movements Assessment and physiological parameters in high risk infants 預防神經發展障礙-高風險嬰兒自動化整體動作評估與生理因子相關性之探討	觀察性研究	N201608042	Sung-Hui Tseng 曾頌惠	丁充達
婦產科	輔助生殖技術	A randomised, controlled, assessor-blind, parallel groups, multicentre, Pan-Asian trial comparing the efficacy and safety of FE 999049 with follitropin alfa (GONAL-F) in controlled ovarian stimulation in women undergoing an assisted reproductive technology programme 一項隨機對照、評估者盲性、平行分組、多中心、泛亞洲試驗，在正接受輔助生殖技術療程的女性中，比較FE 999049用於控制性卵巢刺激時相較於follitropin alfa (GONAL-F) 的療效及安全性	III	N201703075	Chii-Ruey Tzeng 曾啟瑞	李孟樺/呂佳霖
皮膚科	皮膚	明生_Global baby's skin research in Taiwan	其他-醫材	N201803064	Ming-Che Liu 蔡秀欣/陳中明/劉明哲	湯惠珍
骨科	骨折	Asia and Latin America Fracture Observational Study (ALAFOS) 亞洲和拉丁美洲骨折觀察性試驗	NA	N201510027	Yi-Jie Kuo 郭宜潔	藍偉玲 0970-405-675
	Hemophilic 血友病	A Randomized, Double-blind, Placebo-controlled, Proof-of-concept Trial Of Ac-201 Controlled Release Tablets In Subjects With Hemophilic Arthropathy 評估AC-201控釋錠用於血友病關節病變 (hemophilic arthropathy) 患者之隨機、雙盲、安慰劑對照之概念性驗證二期臨床試驗	II	N201611008	Chia-Yau Chang 張家堯	藍偉玲 0970-405-675
		A Randomized, Multicenter, Open-label, Phase Iii Clinical Trial To Evaluate The				徐珮娟

兒科	Hemophilic 血友病	Efficacy, Safety, And Pharmacokinetics Of Prophylactic Emaricizumab Versus No Prophylaxis In Hemophilia A Patients Without Inhibitors 一項隨機分配、多中心、開放性、第三期臨床試驗，評估無抗體的 A 型血友病患者接受 Emicizumab 預防性治療，相較於無預防性治療之療效、安全性和藥物動力學	III	N201611006	Chia-Yau Chang 張家堯	0970-405-546
	Venous Thromboembolism (VTE) 靜脈栓塞(VTE)	A Phase 3, Open-Label, Randomized, Multicenter, Controlled Trial to evaluate the pharmacokinetics and pharmacodynamics of Edoxaban and to compare the efficacy and safety of Edoxaban with standard of care anticoagulant therapy in pediatric subjects from birth to less than 18 years of age with confirmed Venous Thromboembolism (VTE) 一項第三期、開放標示、隨機分配、多中心、對照試驗，經確證診為靜脈栓塞(VTE)之零歲至未滿18歲兒童受試者中，評估 edoxaban 之藥物動力學及藥效學特性，並比較 edoxaban 與標準照護抗凝血療法之療效及安全性	III	N201801053	Chia-Yau Chang 張家堯	藍偉玲 0970-405-675